Cost of prochlorperazine rose 700% after drug companies colluded, alleges watchdogBMJ 2019; 365 doi: https://doi.org/10.1136/bmj.l2362 (Published 28 May 2019) Cite this as: BMJ 2019;365:l2362
- Clare Dyer
- The BMJ
The UK’s competition watchdog has accused four drug companies of unlawfully colluding in an agreement that increased the price of a prescription-only medicine used to treat nausea and dizziness by 700% over four years.
The Competition and Markets Authority (CMA) has provisionally concluded that Alliance, Focus, Lexon, and Medreich agreed not to compete for the supply of prochlorperazine 3 mg buccal or dissolvable tablets to the NHS. The price of a 50 tablet pack rose from £6.49 (€7.36; $8.22) in December 2013 to £51.68 …